116 related articles for article (PubMed ID: 24879095)
21. Obinutuzumab breaks through to FDA approval.
Cancer Discov; 2014 Jan; 4(1):OF6. PubMed ID: 24402958
[TBL] [Abstract][Full Text] [Related]
22. Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.
Ysebaert L; Laprévotte E; Klein C; Quillet-Mary A
Blood Cancer J; 2015 Nov; 5(11):e367. PubMed ID: 26565404
[No Abstract] [Full Text] [Related]
23. Obinutuzumab looks impressive in CLL.
Cancer Discov; 2014 Apr; 4(4):OF5. PubMed ID: 24706674
[No Abstract] [Full Text] [Related]
24. An oral drug for chronic lymphocytic leukemia.
Koehler A
JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
[TBL] [Abstract][Full Text] [Related]
25. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia.
Reda G; Maura F; Gritti G; Gregorini A; Binda F; Guidotti F; Piciocchi A; Visco C; Rodeghiero F; Cortelezzi A
Am J Hematol; 2012 Sep; 87(9):936-7. PubMed ID: 22718434
[TBL] [Abstract][Full Text] [Related]
26. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.
Freeman CL; Morschhauser F; Sehn L; Dixon M; Houghton R; Lamy T; Fingerle-Rowson G; Wassner-Fritsch E; Gribben JG; Hallek M; Salles G; Cartron G
Blood; 2015 Dec; 126(24):2646-9. PubMed ID: 26447188
[No Abstract] [Full Text] [Related]
27. Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.
Walter HS; Jayne S; Mensah P; Miall FM; Lyttelton M; Dyer MJ
Blood Cancer J; 2016 Jun; 6(6):e435. PubMed ID: 27315112
[No Abstract] [Full Text] [Related]
28. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
[TBL] [Abstract][Full Text] [Related]
29. [Subendocardial injury with no evidence of atherosclerosis associated with obinutuzumab infusion].
Santarelli IM; Ibaceta Alaniz EA; Cabo CP; Guarino B; Cordini G; Fernández SI; Melero MJ
Medicina (B Aires); 2021; 81(6):1052-1055. PubMed ID: 34875606
[TBL] [Abstract][Full Text] [Related]
30. [CME Radiology 9. Solution. Multinodular semi-invasive aspergillosis in chronic lymphatic leukemia].
Unterweger M; Otto Ch; Knüsel P
Praxis (Bern 1994); 2005 Sep; 94(37):1449-50. PubMed ID: 16193908
[No Abstract] [Full Text] [Related]
31. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
Kakkar AK; Balakrishnan S
J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
[TBL] [Abstract][Full Text] [Related]
32. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
Byrd JC; Rai KR
Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
[No Abstract] [Full Text] [Related]
33. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
Anoop P; Wotherspoon A; Matutes E
Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
[No Abstract] [Full Text] [Related]
34. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.
Goede V; Fischer K; Busch R; Jaeger U; Dilhuydy MS; Wickham N; De Guibert S; Ritgen M; Langerak AW; Bieska G; Engelke A; Humphrey K; Wenger M; Hallek M
Leukemia; 2013 Apr; 27(5):1172-4. PubMed ID: 22936013
[No Abstract] [Full Text] [Related]
35. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Fiegl M; Stauder R; Steurer M; Mian M; Hopfinger G; Brychtova Y; Skrabs C; Zabernigg A; Schmid F; Haslbaur F; Winder G; Walder A; Lang A; Voskova D; Greil R; Mayer J; Gastl G;
Ann Hematol; 2014 Feb; 93(2):267-77. PubMed ID: 24292560
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.
Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Ann Hematol; 2014 Oct; 93(10):1725-33. PubMed ID: 24844780
[TBL] [Abstract][Full Text] [Related]
38. A fatal case of alemtuzumab-associated interstitial pneumonitis.
Creelan B; Ferber A
Am J Ther; 2008; 15(1):82-4. PubMed ID: 18223357
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Österborg A
Br J Haematol; 2012 Dec; 159(5):608-12. PubMed ID: 23043283
[No Abstract] [Full Text] [Related]
40. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Thachil J; Salim R
Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
